7 Hills Pharma has dosed the first patient in a Phase 1b/2a clinical trial of alintegimod, an integrin-targeted agonist, for solid tumors resistant to immune checkpoint inhibitors.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.